Promising Results Continue to Develop Optimism in Fight Against Cancers - Seite 2
In the second quarter of 2021, J&J's revenue in the pharmaceutical segment grew 13.8% year over year to $12.9 billion. Darzalex, was one of the company's biggest revenue drivers.
Accordingto Jennifer Taubert, Executive Vice President, worldwide chairman of pharmaceuticals at J&J, the company will rely on a combination of established medicines, investigational drugs, and new, innovative therapeutics such as CAR-T meds and gene therapies, on the company's route to becoming a $60-billion-a-year drug maker by 2025. She also told FiercePharmathat Darzalex could soon get a boost from a combination regimen approval in frontline multiple myeloma.
For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a new $900 million cancer and infectious disease dealhas been struck with Norwegian clinical-stage vaccine specialists Nykode (formerly Vaccibody). The collaboration covers multiple targets across five programmes, with three vaccines against cancer. Each of the vaccine candidates would be eligible for milestone and royalty payments.
Prior to the Nykodedeal, Regeneron updated the sectoron their ongoing diverse hematology program in blood cancers and disorders.
"Our hematology portfolio continues to expand with multiple trials now underway to investigate our bispecific antibodies, RNA-based therapies and gene editing, among other approaches," said L. Andres Sirulnik, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Hematology at Regeneron. "Our diverse pipeline includes investigational medicines across several blood cancers including multiple myeloma and lymphoma, in addition to blood disorders such as paroxysmal nocturnal hemoglobinuria, aplastic anemia, amyloidosis and thrombosis. We continue to make progress across our hematology portfolio with eight assets currently in the clinic."
Another potential blockbuster with combo potential is Lumakras from Amgen Inc. (NASDAQ:AMGN)—which was approved by the FDA in May, to become the first and only targeted treatment for patients with KRAS G12C-Mutated locally advanced or metastatic non-small cell lung cancer.
"Lumakras has been prescribed by over 500 oncologists in both academic and community settings. A majority of clinical laboratories have updated their testing reports to reflect KRAS G12C as an actionable mutation, and approximately 75% of patients with non-small cell lung cancer are now being tested for the mutation at the time of diagnosis," saidAmgen's commercial operations chief Murdo Gordon. "I'm very pleased with the Lumakras launch uptake in the U.S."